Bomedemstat
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis
Conditions
Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
Trial Timeline
Jul 18, 2017 → Mar 8, 2022
NCT ID
NCT03136185About Bomedemstat
Bomedemstat is a phase 1/2 stage product being developed by Merck for Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03136185. Target conditions include Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF).
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07049939 | Phase 1 | Completed |
| NCT06351631 | Phase 3 | Recruiting |
| NCT05558696 | Phase 2 | Completed |
| NCT05569538 | Phase 2 | UNKNOWN |
| NCT05223920 | Phase 2 | Completed |
| NCT04254978 | Phase 2 | Completed |
| NCT03136185 | Phase 1/2 | Completed |
Competing Products
20 competing products in Myelofibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 41 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 52 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 77 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 23 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 77 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 52 |
| AZD1480 | AstraZeneca | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Peginterferon alfa-2a | Merck | Phase 2 | 52 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 33 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 33 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 41 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 41 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| ruxolitinib | Novartis | Phase 2 | 52 |